An interventional study of Biomarker-directed treatment for asthma management and Usual Care in Asthma Exacerbations, Biomarkers / Blood and Eosinophil Blood Count, sponsored by National Healthcare Group Polyclinics. Recruiting at 1 site in Singapore. Open to participants aged 21 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-03-20.
Sponsored by National Healthcare Group Polyclinics · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies in Asthma with a site in Singapore — 3 open to participants now, 3 under way, 1 of them phase 3. Asthma · Singapore.
Among the 25 studies in Asthma with a site in Singapore, this one is the 11th largest by planned enrollment of the 19 interventional ones that give a count, is one of 2 that started in 2025, is one of 5 with no phase, and was the 24th registered.
4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.
Browse Asthma studies →3 of the 25 studies in Asthma with a site in Singapore are open now. Recruiting first, the newest first:
Generate Biomedicines · Sites in Singapore, United States, Brazil and 18 more countries
Ages 12–80
Singapore General Hospital · Sites in Singapore
Ages 21–80
A study can be open while its sites in Singapore have not opened yet or have stopped. Only those recruiting at a site in Singapore →
Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.
This study: 21 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 240 is above the median of 79 across 3,346 interventional studies indexed under Asthma.
Median enrollment 253 across the 19 interventional studies, 315 across the 6 observational. Of the 18 that completed or were terminated, 3 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 25 have an industry lead sponsor. The 10 most frequent:
National Healthcare Group Polyclinics is the lead sponsor of 9 studies on the registry; 5 are open to participants now.
National Healthcare Group Polyclinics has 1 study filed under Asthma — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 25 studies in Asthma with a site in Singapore, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this study is to evaluate usual care versus biomarker-directed care (using blood eosinophil counts) for the management of asthma patients in primary care setting.
The study hypothesizes that BEC is a valuable biomarker that can guide asthma treatment, and result in reduction in asthma exacerbations, better symptom control and improvement in quality of life compared to usual arm in mild to moderate asthma patients in the primary care setting.
Researchers would compare using blood eosinophil count guided to usual care to see if biomarker-directed asthma treatment and management
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Asthma management and treatment for participants in this group will be guided by blood eosinophil count (biomarker-directed).
Diagnostic Test: Biomarker-directed treatment for asthma management
Participants in the control arm will receive usual care, this does not involve the use of blood eosinophils
Other: Usual Care
Asthma management and treatment for participants in this group will be guided by blood eosinophil count (biomarker-directed).
Participants in this arm will receive usual asthma care in primary care that does not involve the use of blood eosinophils
Time to first asthma exacerbation requiring hospitalisation
Time to first asthma exacerbation requiring hospitalisation comparing usual care vs biomarker-directed care measured in days.
Time frame: Within 12 months from enrollment
Number of asthma exacerbations not requiring hospitalisation
Number of asthma exacerbations not requiring hospitalisation comparing usual care vs biomarker-directed care measured via counts.
Time frame: From enrollment to 12 months
Worsening of asthma symptoms
Worsening of asthma symptoms based on Asthma Control Test Score (ACT score decrease ≥3 points from baseline) comparing usual care vs biomarker-directed care measured based on scores and percentage of scores.
Time frame: From enrollment to 12 months
Asthma exacerbations requiring systemic corticosteroids and urgent healthcare visits
Asthma exacerbations requiring systemic corticosteroids and urgent healthcare visits (outpatient, ED, admissions) measured via counts.
Time frame: From enrollment to 12 months
Change in Asthma Quality of Life Questionnaire score
Change in asthma quality of life questionnaire (AQLQ) score from baseline measure via score points ranging from 1-7, with higher scores indicating better quality of life.
Time frame: From enrollment to 12 months
Change in Asthma Control Test score
Change in Asthma Control Test (ACT) scores from baseline measure via score points ranging from 5-25, with higher scores indicating better asthma control.
Time frame: From enrollment to 12 months
Change in Global Initiative for Asthma score
Change in Global Initiative for Asthma (GINA) scores from baseline measure via score points ranging from 0-4, with lower scores indicating better asthma control.
Time frame: From enrollment to 12 months
Changes in Forced Expiratory Volume in 1 second
Changes in Forced Expiratory Volume in 1 second (FEV1) from spirometry test, measured in litres, percentages and litres per second. Lower FEV1 value indicates lung obstruction.
Time frame: From enrollment to 12 months
Changes in Forced Vital Capacity
Changes in Forced Vital Capacity (FVC) from spirometry test, measured in litres, percentages and litres per second. Lower FVC value indicates lung obstruction.
Time frame: From enrollment to 12 months
Changes in Forced Expiratory Volume in 1 second/Forced Vital Capacity Ratio
Changes in Forced Expiratory Volume in 1 second (FEV1)/Forced Vital Capacity (FVC) ratio from spirometry test, measured in litres, percentages and litres per second. FEV1/FVC below 0.70 typically indicates airway obstruction.
Time frame: From enrollment to 12 months
Changes in Peak Expiratory Flow
Changes in Peak Expiratory Flow (PEF) from spirometry test, measured in litres, percentages and litres per second. Higher PEF value indicates good asthma control.
Time frame: From enrollment to 12 months
Plan to share: No
No publications or documents are linked to this record.
Started Dec 2025 (actual). Primary completion is estimated for Dec 2028, 36 months after the start.
Of 601 non-industry interventional studies with no phase under Asthma, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 50. This study's planned 36 months is above that.
Counting every sponsor, half of 651 studies reached it within 23 months; a quarter within 10 and three quarters within 47.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National Healthcare Group Polyclinics